Scientists are calling for stage 3 clinical trials of an Alzheimer's drug to be scrapped after a report highlighted serious doubts about the legitimacy of research that helped the medicine reach that stage.A long-awaited report by the City University of New York (CUNY) accused one of its faculty members, neuroscientist Hoau-Yan Wang, of egregious misconduct concerning 20 research papers — defined as workplace behavior so outrageous, dangerous, or illegal that an employer cannot reasonably expect to correct it through progressive discipline.According to the 50-page document obtained by Science, Mr Wang could not provide original data to disprove in his research papers, many of which provided critical support for the Alzheimer's drug simufilam's jump from the lab into clinical studies.
Load More
Load More